Anti-CCP antibodies predict progression of palindromic rheumatism to rheumatoid arthritis.
- Author:
Ji Young KIM
1
;
Sung Hoon PARK
;
Seong Kyu KIM
;
Sang Gyung KIM
;
Im Hee SHIN
;
Jung Yoon CHOE
Author Information
1. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. jychoe@cu.ac.kr
- Publication Type:Original Article
- Keywords:
Palindromic Rheumatism;
Anti-CCP antibody
- MeSH:
Antibodies;
Arthritis, Rheumatoid;
HLA-DR4 Antigen;
Humans;
Logistic Models;
Rheumatic Diseases;
Risk Factors
- From:Korean Journal of Medicine
2009;76(2):193-198
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Palindromic rheumatism (PR) is an episodic arthropathy that may precede typical rheumatoid arthritis (RA). The objective of this study was to determine whether anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with PR contribute to the progression to RA. METHODS: The study group included 115 patients who were initially diagnosed with PR. Baseline serum samples were stored and analyzed for the presence of anti-CCP antibodies, APF, and RF or for anti-CCP antibodies and HLA-DR4. A multiple logistic regression analysis was used to identify predictive factors for progression to RA. RESULTS: The anti-CCP antibodies APF and RF were found in 33.3%, 28.9%, and 35.7% of the 115 patients with PR, and 36 (31.3%) of these patients eventually progressed to RA. Comparing the risk factors for patients who progressed to RA (31.3%) and those who did not (68.7%), only the presence of anti-CCP antibodies was found to affect progression to RA (95% CI for OR, 0.0001-0.114; p<0.001). HLA-DR4-positivity was noted in 40% of the patients with PR, although it did not affect progression to RA and was not significantly associated with the presence of anti-CCP antibodies. CONCLUSIONS: Anti-CCP antibodies are found more frequently in patients with PR who eventually progress to RA. Therefore, anti-CCP antibody testing of patients with PR may facilitate prediction of progression to RA.
